Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 3 of 6 for:    Open Studies | "Proctitis"

Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Dr. Falk Pharma GmbH
Sponsor:
Information provided by (Responsible Party):
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
NCT01966783
First received: October 9, 2013
Last updated: May 14, 2014
Last verified: May 2014
  Purpose

The purpose of this study is to investigate the efficacy and safety of budesonide suppository for the treatment of acute ulcerative proctitis.


Condition Intervention Phase
Proctitis
Drug: Budesonide 2 mg suppository
Drug: Budesonide 4 mg suppository
Drug: Mesalazine 1 g suppository
Drug: Budesonide 2 mg suppository/Mesalazine 1 g suppository
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis

Resource links provided by NLM:


Further study details as provided by Dr. Falk Pharma GmbH:

Primary Outcome Measures:
  • Resolution of clinical symptoms [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Symptoms as reported in the diary


Secondary Outcome Measures:
  • Rate of clinical and endoscopic remission [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Symptoms as reported in the diary, ulcerative colitis-disease activity index

  • Rate of improvement [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Symptoms as reported in the diary, ulcerative colitis-disease activity index

  • Rate of patients with clinical remission [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Symptoms as reported in the diary, ulcerative colitis-disease activity index

  • Rate of patients with endoscopic remission [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Ulcerative colitis-disease activity index


Estimated Enrollment: 320
Study Start Date: September 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Budesonide dosage 1
Budesonide 2 mg suppository
Drug: Budesonide 2 mg suppository
per day
Experimental: Budesonide dosage 2
Budesonide 4 mg suppository
Drug: Budesonide 4 mg suppository
per day
Active Comparator: Mesalazine
Mesalazine 1g suppository
Drug: Mesalazine 1 g suppository
per day
Experimental: Combination
Budesonide 2 mg suppository/Mesalazine 1 g suppository
Drug: Budesonide 2 mg suppository/Mesalazine 1 g suppository
per day

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Active ulcerative proctitis
  • Diagnosis confirmed by endoscopy
  • Established disease or new diagnosis

Exclusion Criteria:

  • Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular assoc. colitis, microscopic colitis
  • Presence of proctitis of a different origin
  • Prior bowel resection
  • Presence of symptomatic organic disease of the gastrointestinal tract
  • Asthma, tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection if careful medical monitoring is not ensured
  • Local intestinal infection
  • Abnormal hepatic or renal function
  • Oral/rectal/intravenous corticosteroids therapy
  • Existing or intended pregnancy or breast-feeding
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01966783

Contacts
Contact: Ralf Mohrbacher, MSc ++49-761-1514-0 ext 156 mohrbacher@drfalkpharma.de
Contact: Roland Greinwald, PhD ++49-761-1514-0 ext 0 greinwald@drfalkpharma.de

Locations
Germany
Charité-Campus Benjamin Franklin Universitätsmedizin Berlin Recruiting
Berlin, Germany, 12203
Contact: Britta Siegmund, Professor    ++40 30 450514 ext 322    britta.siegmund@charite.de   
Principal Investigator: Britta Siegmund, Professor         
Evang. Krankenhaus Kalk, Medical Department Recruiting
Cologne, Germany, 51103
Contact: Wolfgang Kruis, Professor    ++49 221 8289 ext 5289    kruis@evkk.de   
Principal Investigator: Wolfgang Kruis, Professor         
Sponsors and Collaborators
Dr. Falk Pharma GmbH
Investigators
Principal Investigator: Wolfgang Kruis, Professor Evang. Krankenhaus Kalk, Medical Department
Principal Investigator: Britta Siegmund, Professor Charité-Campus Benjamin Franklin Universitätsmedizin Berlin
  More Information

No publications provided

Responsible Party: Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier: NCT01966783     History of Changes
Other Study ID Numbers: BUS-2/UCA, 2012-003362-41
Study First Received: October 9, 2013
Last Updated: May 14, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Proctitis
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Budesonide
Mesalamine
Analgesics
Analgesics, Non-Narcotic
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Autonomic Agents
Bronchodilator Agents
Central Nervous System Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014